Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Breast Cancer Expert Offers Views on Promising Strategies

April 1st 2014

Now that targeted therapies are available for the treatment of various subtypes of breast cancer, and many novel agents are under investigation, it is important for the oncology community to follow the latest advancements to give patients the best available options.

Next-Generation EGFR Inhibitor Shows Promise in Resistant NSCLC

March 31st 2014

The next-generation EGFR inhibitor CO-1686 has demonstrated promising activity in T790M-positive patients with non-small cell lung cancer.

Precision Medicine-An Inevitable (Though Challenging) Goal!

March 26th 2014

There is no question that the era of precision medicine has arrived, and we need to embrace it and resolve together the challenges that come with it, including at the regulatory level.

Some Docs Hesitant to Embrace Genomic Tests That Identify Tumor Changes

March 25th 2014

A physician's confidence level in his genomic knowledge plays a significant role in attitudes towards genomic tests, especially in tests that look for changes in DNA that are taken from patients' tumor samples

Dr. Oh on a Biomarker Development Trial in mCRPC

March 20th 2014

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial in metastatic castrate-resistant prostate cancer (mCRPC).

Dr. Tripathy on Personalized Therapies in Advanced BC

March 20th 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses new personalized therapies on the horizon for advanced breast cancer.

Conclusion: Optimizing the Treatment of RCC

March 19th 2014

RCC Journal Highlights and Implications for Clinical Practice

March 19th 2014

Novel Therapies in Renal Cell Carcinoma

March 19th 2014

Evolving Role of Genomic Testing in RCC

March 19th 2014

Case Study: Utilizing Multiple Therapies in mRCC

March 19th 2014

Drug Holidays in Renal Cell Carcinoma

March 19th 2014

Case Study: Observation in Metastatic RCC

March 19th 2014

Case Study: Treating Progressive Renal Cell Carcinoma

March 19th 2014

Second-Line Angiogenesis Inhibition in mRCC

March 19th 2014

Second-Line Treatment of Metastatic Renal Cell Carcinoma

March 19th 2014

Optimizing the Upfront Treatment of mRCC

March 19th 2014

Cytoreductive Nephrectomy in Untreated Metastatic RCC

March 19th 2014

Frontline Treatment of Poor-Risk mRCC

March 19th 2014

Treatment of Metastatic Non-Clear Cell RCC

March 19th 2014